Manuela Valente Sells 2,376 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 2,376 shares of SOPHiA GENETICS stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total value of $11,571.12. Following the completion of the sale, the insider owned 219,275 shares in the company, valued at approximately $1,067,869.25. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 6th, Manuela Valente sold 2,597 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $12,595.45.
• On Thursday, March 19th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $1,820.20.

SOPHiA GENETICS Trading Down 0.3%

Shares of SOPH stock traded down $0.01 during trading hours on Wednesday, reaching $4.89. The company’s stock had a trading volume of 64,929 shares, compared to its average volume of 188,371. The stock has a market capitalization of $334.64 million, a P/E ratio of -9.58 and a beta of 1.04. SOPHiA GENETICS SA has a one year low of $2.58 and a one year high of $5.70. The firm’s fifty day simple moving average is $4.78 and its 200 day simple moving average is $4.68. The company has a current ratio of 1.96, a quick ratio of 1.84 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to the consensus estimate of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. Equities research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after purchasing an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC boosted its holdings in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares in the last quarter. Alta Wealth Advisors LLC bought a new stake in SOPHiA GENETICS in the third quarter worth $6,708,000. Royce & Associates LP bought a new stake in SOPHiA GENETICS in the fourth quarter worth $2,009,000. Finally, 1492 Capital Management LLC bought a new stake in SOPHiA GENETICS in the fourth quarter worth $973,000. 31.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on SOPH. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Guggenheim lifted their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Finally, BTIG Research restated a “buy” rating and set a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.